Logo image of KIN.BR

KINEPOLIS (KIN.BR) Stock Fundamental Analysis

EBR:KIN - BE0974274061 - Common Stock

33 EUR
+0.05 (+0.15%)
Last: 9/3/2025, 7:00:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to KIN. KIN was compared to 42 industry peers in the Entertainment industry. There are concerns on the financial health of KIN while its profitability can be described as average. KIN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

KIN had positive earnings in the past year.
In the past year KIN had a positive cash flow from operations.
In multiple years KIN reported negative net income over the last 5 years.
Of the past 5 years KIN 4 years had a positive operating cash flow.
KIN.BR Yearly Net Income VS EBIT VS OCF VS FCFKIN.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

KIN has a Return On Assets of 4.54%. This is in the better half of the industry: KIN outperforms 69.05% of its industry peers.
KIN has a Return On Equity of 23.61%. This is amongst the best in the industry. KIN outperforms 85.71% of its industry peers.
KIN's Return On Invested Capital of 8.28% is fine compared to the rest of the industry. KIN outperforms 73.81% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for KIN is below the industry average of 10.22%.
The 3 year average ROIC (6.76%) for KIN is below the current ROIC(8.28%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.54%
ROE 23.61%
ROIC 8.28%
ROA(3y)3.57%
ROA(5y)0.53%
ROE(3y)21.42%
ROE(5y)-2.24%
ROIC(3y)6.76%
ROIC(5y)N/A
KIN.BR Yearly ROA, ROE, ROICKIN.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

KIN's Profit Margin of 7.98% is fine compared to the rest of the industry. KIN outperforms 73.81% of its industry peers.
KIN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 15.19%, KIN belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
In the last couple of years the Operating Margin of KIN has declined.
KIN has a worse Gross Margin (24.54%) than 90.48% of its industry peers.
KIN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.19%
PM (TTM) 7.98%
GM 24.54%
OM growth 3YN/A
OM growth 5Y-4.79%
PM growth 3YN/A
PM growth 5Y-6.62%
GM growth 3Y115.73%
GM growth 5Y-3.42%
KIN.BR Yearly Profit, Operating, Gross MarginsKIN.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KIN is creating some value.
The number of shares outstanding for KIN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, KIN has more shares outstanding
KIN has a better debt/assets ratio than last year.
KIN.BR Yearly Shares OutstandingKIN.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KIN.BR Yearly Total Debt VS Total AssetsKIN.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.60, we must say that KIN is in the distress zone and has some risk of bankruptcy.
KIN has a Altman-Z score of 1.60. This is in the better half of the industry: KIN outperforms 61.90% of its industry peers.
KIN has a debt to FCF ratio of 5.38. This is a neutral value as KIN would need 5.38 years to pay back of all of its debts.
KIN has a Debt to FCF ratio (5.38) which is comparable to the rest of the industry.
KIN has a Debt/Equity ratio of 2.87. This is a high value indicating a heavy dependency on external financing.
KIN has a Debt to Equity ratio of 2.87. This is in the lower half of the industry: KIN underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF 5.38
Altman-Z 1.6
ROIC/WACC1.6
WACC5.17%
KIN.BR Yearly LT Debt VS Equity VS FCFKIN.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 0.47 indicates that KIN may have some problems paying its short term obligations.
KIN's Current ratio of 0.47 is on the low side compared to the rest of the industry. KIN is outperformed by 83.33% of its industry peers.
A Quick Ratio of 0.44 indicates that KIN may have some problems paying its short term obligations.
KIN has a Quick ratio of 0.44. This is amonst the worse of the industry: KIN underperforms 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.44
KIN.BR Yearly Current Assets VS Current LiabilitesKIN.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

5

3. Growth

3.1 Past

KIN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.32%, which is quite impressive.
KIN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.80% yearly.
KIN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.38%.
KIN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.95% yearly.
EPS 1Y (TTM)34.32%
EPS 3YN/A
EPS 5Y-5.8%
EPS Q2Q%5581.82%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y29.47%
Revenue growth 5Y0.95%
Sales Q2Q%6.22%

3.2 Future

Based on estimates for the next years, KIN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.11% on average per year.
Based on estimates for the next years, KIN will show a small growth in Revenue. The Revenue will grow by 4.98% on average per year.
EPS Next Y37.47%
EPS Next 2Y27.44%
EPS Next 3Y21.34%
EPS Next 5Y15.11%
Revenue Next Year5.79%
Revenue Next 2Y6%
Revenue Next 3Y5.25%
Revenue Next 5Y4.98%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KIN.BR Yearly Revenue VS EstimatesKIN.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
KIN.BR Yearly EPS VS EstimatesKIN.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 19.30 indicates a rather expensive valuation of KIN.
85.71% of the companies in the same industry are more expensive than KIN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of KIN to the average of the S&P500 Index (26.84), we can say KIN is valued slightly cheaper.
A Price/Forward Earnings ratio of 12.12 indicates a correct valuation of KIN.
Based on the Price/Forward Earnings ratio, KIN is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.
KIN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.48.
Industry RankSector Rank
PE 19.3
Fwd PE 12.12
KIN.BR Price Earnings VS Forward Price EarningsKIN.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

KIN's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of KIN indicates a rather cheap valuation: KIN is cheaper than 80.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.92
EV/EBITDA 8.98
KIN.BR Per share dataKIN.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KIN's earnings are expected to grow with 21.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y27.44%
EPS Next 3Y21.34%

3

5. Dividend

5.1 Amount

KIN has a Yearly Dividend Yield of 1.11%. Purely for dividend investing, there may be better candidates out there.
KIN's Dividend Yield is a higher than the industry average which is at 2.05.
With a Dividend Yield of 1.11, KIN pays less dividend than the S&P500 average, which is at 2.32.
Industry RankSector Rank
Dividend Yield 1.11%

5.2 History

The dividend of KIN decreases each year by -3.32%.
Dividend Growth(5Y)-3.32%
Div Incr Years1
Div Non Decr Years2
KIN.BR Yearly Dividends per shareKIN.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

KIN pays out 31.09% of its income as dividend. This is a sustainable payout ratio.
DP31.09%
EPS Next 2Y27.44%
EPS Next 3Y21.34%
KIN.BR Yearly Income VS Free CF VS DividendKIN.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M
KIN.BR Dividend Payout.KIN.BR Dividend Payout, showing the Payout Ratio.KIN.BR Dividend Payout.PayoutRetained Earnings

KINEPOLIS

EBR:KIN (9/3/2025, 7:00:00 PM)

33

+0.05 (+0.15%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-21 2025-08-21
Earnings (Next)N/A N/A
Inst Owners15.64%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner ChangeN/A
Market Cap903.21M
Analysts86
Price Target49.64 (50.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.11%
Yearly Dividend0.54
Dividend Growth(5Y)-3.32%
DP31.09%
Div Incr Years1
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.61%
EPS NY rev (3m)-7.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-1.13%
Valuation
Industry RankSector Rank
PE 19.3
Fwd PE 12.12
P/S 1.52
P/FCF 6.92
P/OCF 5.21
P/B 4.51
P/tB 40.3
EV/EBITDA 8.98
EPS(TTM)1.71
EY5.18%
EPS(NY)2.72
Fwd EY8.25%
FCF(TTM)4.77
FCFY14.46%
OCF(TTM)6.34
OCFY19.21%
SpS21.68
BVpS7.32
TBVpS0.82
PEG (NY)0.52
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.54%
ROE 23.61%
ROCE 11.27%
ROIC 8.28%
ROICexc 8.93%
ROICexgc 11.76%
OM 15.19%
PM (TTM) 7.98%
GM 24.54%
FCFM 22.02%
ROA(3y)3.57%
ROA(5y)0.53%
ROE(3y)21.42%
ROE(5y)-2.24%
ROIC(3y)6.76%
ROIC(5y)N/A
ROICexc(3y)7.02%
ROICexc(5y)N/A
ROICexgc(3y)8.91%
ROICexgc(5y)N/A
ROCE(3y)9.19%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-1%
ROICexc growth 3YN/A
ROICexc growth 5Y-1.69%
OM growth 3YN/A
OM growth 5Y-4.79%
PM growth 3YN/A
PM growth 5Y-6.62%
GM growth 3Y115.73%
GM growth 5Y-3.42%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF 5.38
Debt/EBITDA 3.35
Cap/Depr 52.23%
Cap/Sales 7.23%
Interest Coverage 4.1
Cash Conversion 100.75%
Profit Quality 276.05%
Current Ratio 0.47
Quick Ratio 0.44
Altman-Z 1.6
F-Score8
WACC5.17%
ROIC/WACC1.6
Cap/Depr(3y)43.12%
Cap/Depr(5y)41.32%
Cap/Sales(3y)6.29%
Cap/Sales(5y)10.19%
Profit Quality(3y)301.12%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.32%
EPS 3YN/A
EPS 5Y-5.8%
EPS Q2Q%5581.82%
EPS Next Y37.47%
EPS Next 2Y27.44%
EPS Next 3Y21.34%
EPS Next 5Y15.11%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y29.47%
Revenue growth 5Y0.95%
Sales Q2Q%6.22%
Revenue Next Year5.79%
Revenue Next 2Y6%
Revenue Next 3Y5.25%
Revenue Next 5Y4.98%
EBIT growth 1Y16.5%
EBIT growth 3YN/A
EBIT growth 5Y-3.89%
EBIT Next Year112.63%
EBIT Next 3Y32.23%
EBIT Next 5Y22.36%
FCF growth 1Y30.27%
FCF growth 3Y19%
FCF growth 5Y6.53%
OCF growth 1Y26.43%
OCF growth 3Y22.57%
OCF growth 5Y1.63%